Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research

​Program 

Monday, April 29

Tuesday, April 30


Monday, April 29

Continental Breakfast
7-8 a.m.

Opening Session and Keynote Lecture #1 
8-9:30 a.m.

Welcome Remarks
James W. Rocco, The Ohio State University Wexner Medical Center, Columbus, Ohio

In Memoriam: Drs. Waun Ki Hong and John Mendelsohn
Christine H. Chung, Moffitt Cancer Center, Tampa, Florida

Cancer evolution through the lens of single cell genomics
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas


Break
9:30-9:55 a.m.


Plenary Session 1: Novel Targets and Biomarkers in Head and Neck Cancer 
Session Chair: Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, Texas
9:55 a.m.-12 p.m.

Utilizing patient-derived xenografts for prognostication and biomarker discovery
Laurie E. Ailles, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Genetic and immunogenomic biomarkers in advanced head and neck cancer
Luc G.T. Morris, Memorial Sloan Kettering Cancer Center, New York, New York

Novel approaches to study the tumor-stroma interaction and translate immune-directed therapies        
Antonio Jimeno, University of Colorado Cancer Center, Aurora, Colorado

Intratumor genetic heterogeneity as a predictive biomarker in head and neck squamous cell carcinoma
James W. Rocco, The Ohio State University Wexner Medical Center, Columbus, Ohio

HPV structure and functional alterations impact prognosis in HPV (+) oropharyngeal squamous cell carcinoma*
Jose P. Zevallos, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status*
Anthony Nichols, Western University, London, Ontario, Canada


Free Time (Lunch on Own)
12-1:45 p.m.


Grant Education Session (Optional)
12:30-1:30 p.m.

Head and neck cancer research investment at NIDCR
Chiayeng Wang, National Institute of Dental and Craniofacial Research, Bethesda, Maryland

Panel Discussion on Grant Writing
Patrick K. Ha, University of California San Francisco, San Francisco, California
Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, Texas
Richard J. Wong, Memorial Sloan Kettering Cancer Center, New York, New York
Jose P. Zevallos, Washington University School of Medicine in St. Louis, St. Louis, Missouri


Keynote Lecture #2
1:45-2:30 p.m.

Understanding tumor dynamics and heterogeneity
Gad Getz, Broad Institute of MIT and Harvard, Cambridge, Massachusetts


Plenary Session 2: Single Cell Analysis
Session Chair: Wendell G. Yarbrough, University of North Carolina School of Medicine, Chapel Hill, North Carolina
2:30-4:10 p.m.

Solving biomedical challenges through single cell genomics approach
Alexandra Chloe Villani, Broad Institute of MIT and Harvard, Cambridge, Massachusetts

Understanding programs of invasion and metastasis in head and neck cancer
Sidharth V. Puram, Washington University in St. Louis, St. Louis, Missouri

Beyond counting: Imaging flow cytometry-based detection of therapeutic molecular targets in circulating tumor cells
Ingeborg Tinhofer, Charité – Universitätsmedizin Berlin, Berlin, Germany

The tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC): Investigating new aspects of known cell types using single cell RNA sequencing*
Aditi Kulkarni, University of Pittsburgh, Pittsburgh, Pennsylvania

RNA sequencing of salivary mucoepidermoid carcinoma reveals distinct molecular profiles based on histological grade*
Siddharth Sheth, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina


Break
4:10-4:40 p.m.


Plenary Session 3: TME / Metabolomics / Hypoxia
Session Chair: Jose P. Zevallos, Washington University School of Medicine in St. Louis, St. Louis, Missouri
4:40-6:20 p.m.

Targeting glutamine metabolism as a means of enhancing immunotherapy for cancer
Jonathan D. Powell, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Reversal of immunotherapy resistance through hypoxia reduction
Michael A. Curran, The University of Texas MD Anderson Cancer Center, Houston, Texas

Metabolic barriers to effective immunotherapy of cancer
Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, Pennsylvania

Effects of tobacco smoking on the tumor microenvironment in head and neck squamous cell carcinoma
Christine H. Chung, Moffitt Cancer Center, Tampa, Florida


Poster Session A / Reception
6:25-8 p.m.


Tuesday, April 30

Continental Breakfast
7-8 a.m.


Keynote Lecture #3
8-8:45 a.m.

Targeting the DNA damage response in head and neck cancers
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas


Plenary Session 4: Immune Checkpoint Blockade in Cancer Therapies / Immunobiology / Targeting the Immune System
Session Chair: Robert L. Ferris, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania
8:45-10:50 a.m.

Suppression of intratumoral regulatory T cells restores radiosensitivity in head and neck cancer: Role for Stat3 inhibition   
Sana D. Karam, University of Colorado Denver, Aurora, Colorado

Augmenting anti-PD1 activity via an HLA-agnostic, mutation-burden independent, personalized neoantigen vaccine strategy
Ezra E.W. Cohen, UCSD Moores Cancer Center, San Diego, California

Cellular interactions and regulatory mechanisms in head and neck cancer
Dario A. Vignali, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Interrogating anti-PD1 immunotherapy resistance mechanisms
Ravindra Uppaluri, Dana-Farber Cancer Center, Boston, Massachusetts

APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma*
Daniel Faden, Massachusetts Eye-Ear Infirmary, Boston, Massachusetts

Tumor infiltrating B cells co-localize with CD4 T effector cells within tertiary lymphoid structures to present antigen and educate the anti-tumor immune response in human primary tumors*
Tullia Bruno, University of Pittsburgh, Pittsburgh, Pennsylvania


Break
10:50-11:05 a.m.


Plenary Session 5: Updates on Clinical Trials
Session Chair: Cherie-Ann O. Nathan, Louisiana State University Health Sciences Center, Shreveport, Louisiana
11:05 a.m.-12:25 p.m.

Immune checkpoint inhibition in metastatic/recurrent head and neck cancer
Barbara A. Burtness, Yale Cancer Center, New Haven, Connecticut

Radiotherapy plus cetuximab or cisplatin in human papilloma-virus positive oropharyngeal cancer (NRG 1016): A randomized multicenter non-inferiority trial
Andy M. Trotti, Moffitt Cancer Center, Tampa, Florida

Integrating head and neck cancer immunotherapy into locally advanced treatment
Robert L. Ferris, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania

Panel Discussion


Poster Session B / Lunch
12:25-1:55 p.m.


Plenary Session 6: Mechanisms of Therapy Response and Resistance
Session Chair: Joseph A. Califano, UCSD, La Jolla, California
1:55-4 p.m.

Understanding genetic mediators of response and resistance to immune checkpoint blockade therapy
Nadeem Riaz, Memorial Sloan Kettering Cancer Center, New York, New York

Intrinsic tumor genomic and metabolic factors leading to immunoresistance    
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Molecular correlates of T cell-inflamed and non-T cell-inflamed tumors
Jason J. Luke, University of Pittsburgh Medical Center and Hillman Cancer Center, Pittsburgh, Pennsylvania

Radiation as a way to flip the switch: Resistance to responder in HNSCC
David Raben, University of Colorado Cancer Center, Aurora, Colorado

WEE1 inhibition triggers premature mitotic entry in HPV16-E6 expressing cells independent of p53*
Ahmed Diab, Fred Hutchinson Cancer Research Center, Seattle, Washington

Inhibition of ATR as a therapeutic strategy to overcome cisplatin resistance in HNSCC*
Antje Lindemann, The University of Texas MD Anderson Cancer Center, Houston, Texas


Closing Remarks
4 p.m.

Neil D. Gross, The University of Texas MD Anderson Cancer Center, Houston, Texas


*Short talk from proffered abstract


Top of page